共 50 条
Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
被引:5
|作者:
Lawson, Alexander
[1
]
Kamarajah, Sivesh K.
[2
]
Parente, Alessandro
[2
]
Pufal, Kamil
[1
]
Sundareyan, Ramanivas
[3
]
Pawlik, Timothy M.
[4
]
Ma, Yuk Ting
[5
]
Shah, Tahir
[6
]
Kharkhanis, Salil
[3
]
Dasari, Bobby V. M.
[2
,7
]
机构:
[1] Univ Birmingham, Birmingham Med Sch, Birmingham B15 2TT, England
[2] Queen Elizabeth Hosp, Dept HPB & Liver Transplantat, Birmingham B15 2TH, England
[3] Queen Elizabeth Hosp, Dept Radiol, Birmingham B15 2TH, England
[4] Ohio State Univ, Wexner Med Ctr, Dept Surg, Columbus, OH 43210 USA
[5] Queen Elizabeth Hosp, Dept Oncol, Birmingham B15 2TH, England
[6] Queen Elizabeth Hosp, Liver Unit, Birmingham B15 2TH, England
[7] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham B15 2TT, England
来源:
关键词:
hepatocellular carcinoma;
transarterial embolisation;
transarterial chemoembolisation;
TRANSCATHETER ARTERIAL EMBOLIZATION;
DRUG-ELUTING BEADS;
CONVENTIONAL CHEMOEMBOLIZATION;
BLAND EMBOLIZATION;
TRIAL;
D O I:
10.3390/cancers15123166
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Simple Summary Non-surgical management of hepatocellular carcinoma (HCC) is used for selected patients. Of these management options, transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) are the two main locoregional treatment options. There was no difference in OS among patients treated with TACE/TAE, single versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has a comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs, which are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future. Although hepatocellular carcinoma is increasingly common, debate exists surrounding the management of patients with unresectable disease comparing transarterial embolisation (TAE) or transarterial chemoembolisation (TACE). This study aimed to compare the outcomes of patients receiving TAE and TACE. A systematic review was performed using PubMed, Medline, Embase, and Cochrane databases to identify randomised controlled trials (RCTs) until August 2021. The primary outcome was overall survival (OS) and the secondary outcomes were progression-free survival (PFS) and adverse events. Five studies with 609 patients were included in the analysis. There was no statistically significant difference in the OS (p = 0.36) and PFS (p = 0.81). There was no difference in OS among patients treated with a single TACE/TAE versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future.
引用
收藏
页数:11
相关论文